{"id":"NCT03450629","sponsor":"Sun Pharma Advanced Research Company Limited","briefTitle":"Evaluation of Safety and Efficacy of PDP-716","officialTitle":"A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-PÂ® in Subjects With Open Angle Glaucoma, or Ocular Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-09-13","primaryCompletion":"2020-12-01","completion":"2020-12-01","firstPosted":"2018-03-01","resultsPosted":"2022-02-15","lastUpdate":"2022-02-15"},"enrollment":682,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Open Angle Glaucoma","Ocular Hypertension"],"interventions":[{"type":"DRUG","name":"Brimonidine Tartrate Ophthalmic Suspension","otherNames":[]},{"type":"DRUG","name":"Brimonidine Tartrate Ophthalmic Solution","otherNames":[]}],"arms":[{"label":"PDP-716","type":"EXPERIMENTAL"},{"label":"Brimonidine Tartrate Ophthalmic Solution","type":"ACTIVE_COMPARATOR"}],"summary":"The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.","primaryOutcome":{"measure":"Change From Baseline in Mean Intraocular Pressure","timeFrame":"Week 12 8 AM, 10 AM and 4 PM","effectByArm":[{"arm":"PDP-716","deltaMin":20.35,"sd":3.746},{"arm":"Brimonidine Tartrate Ophthalmic Solution","deltaMin":20.79,"sd":3.724}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0006"},{"comp":"OG000 vs OG001","p":"0.0291"},{"comp":"OG000 vs OG001","p":"0.0002"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":47,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":337},"commonTop":["Somnolence","Conjunctivitis","Conjunctival hyperaemia","Vision blurred"]}}